Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Article Commentary
Authors: Digma, Leonardino A. | Winer, Joseph R. | Greicius, Michael D.; *
Affiliations: Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA
Correspondence: [*] Correspondence to: Dr. Michael D. Greicius, MD, Wu Tsai Neurosciences Institute, 290 Jane Stanford Way, Stanford, CA 94305-5090, USA. Tel.: +1 650 498 4624; E-mail: [email protected].
Abstract: With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusiasm for anti-amyloid antibodies in the treatment of Alzheimer’s disease. Here, we discuss three substantial limitations regarding recent anti-amyloid clinical trials: 1) there is little evidence that amyloid reduction correlates with clinical outcome, 2) the reported efficacy of anti-amyloid therapies may be explained by functional unblinding, and 3) donanemab had no effect on tau burden in its phase 3 trial. Taken together, these observations call into question the efficacy of anti-amyloid therapies.
Keywords: Alzheimer’s disease, amyloid, clinical trials, tau
DOI: 10.3233/JAD-231198
Journal: Journal of Alzheimer's Disease, vol. 97, no. 2, pp. 567-572, 2024
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]